REMS: To outsource or not to outsource?

Key considerations for building and managing an effective REMS

Risk evaluation and mitigation strategies (REMS) play an important role in supporting the safe use of certain prescription medicines with serious safety concerns. While the U.S. Food and Drug Administration (FDA) ultimately determines whether a REMS is necessary, sponsors should remain informed of evolving regulatory guidance, industry trends, and changes in health care deliver that continue to shape REMS design, implementation, assessment, and lifecycle management.

Once the FDA determines that a REMS is required, sponsors face the important task of developing a program that is purposefully designed to mitigate the specific serious risks that require additional risk management measures while supporting the safe use of the product and appropriate patient access. No two REMS look exactly alike because no two products have the same benefit risk profile or require the same risk mitigation strategy. Every REMS should generate meaningful evidence demonstrating that it is achieving its intended risk mitigation objectives throughout the product lifecycle.

This blog highlights the key considerations sponsors should evaluate when deciding whether to outsource REMS administration or develop the capabilities to manage a REMS internally.

REMS program: A cross-functional challenge

Implementing and managing a REMS requires specialized knowledge and expertise. Depending on the REMS requirements, organizations may need expertise across regulatory affairs, pharmacovigilance, epidemiology, risk management, medical writing, information technology, quality, legal, finance, commercial operations, and project management.

One of the first considerations is whether these capabilities exist within the organization and whether those resources have direct REMS experience. Developing an effective REMS requires more than operational execution. It requires understanding the product’s benefit risk profile, identifying the behaviors necessary to support safe use, and ensuring that every REMS requirement contributes to mitigating the identified risks.

The FDA’s REMS Logic Model reinforces this approach by encouraging sponsors to establish clear program objectives, define the actions necessary to support safe use and incorporate assessment planning early in REMS development. Building assessment planning into the design of a REMS ensures sponsors collect meaningful evidence demonstrating whether the REMS is achieving its intended objectives while identifying opportunities for continuous improvement over time.

Organizations managing one or two REMS programs may find it difficult to maintain dedicated expertise across multiple disciplines. Selecting the right REMS administrator should be about more than supplementing operational resources. The most effective REMS administrators become strategic business partners, providing scientific, regulatory, operational, and technology expertise that enables sponsors to design, implement, assess, and continuously improve their REMS throughout the product life cycle.

Alignment across internal stakeholders is equally important. Different departments often have different priorities and decision-making processes. Establishing effective governance early helps ensure alignment throughout implementation, assessments and future REMS modifications.

For shared system REMS, governance becomes even more critical. Experienced project management can provide objective coordination among participating sponsors, facilitate consensus-driven planning, and manage the operational complexities associated with maintaining a shared REMS.

Role of technology for a REMS

Technology continues to play an increasingly important role in REMS administration.

While websites, contact centers, databases, and fulfillment remain important operational components, modern REMS technology should also offer secure stakeholder enrollment, workflow automation, electronic signatures, audit trails, configurable reporting, and meaningful data that support REMS assessments and regulatory reporting.

Developing and maintaining this infrastructure internally requires significant investment, ongoing system validation, cybersecurity oversight, and continuous enhancements to address changing business and regulatory expectations.

When evaluating whether to build technology internally or outsource REMS administration, sponsors should consider not only implementation costs, but also the ongoing investment required to maintain validated systems, support inspections, protect sensitive data, and respond to evolving regulatory expectations.

For sponsors who are not able to incur this added cost, our risk assessment and mitigation platform supports these evolving needs through configurable workflows, secure stakeholder management, operational dashboards, audit capabilities, and real-time reporting that provide greater visibility into REMS performance. By combining configurable technology with experienced REMS professionals, sponsors gain meaningful operational insights that support informed decision making, strengthen program oversight, facilitate REMS assessments, and help programs evolve throughout the product lifecycle.

Technology alone does not create an effective REMS. Its greatest value is realized when combined with experienced REMS professionals who can translate operational data into meaningful program insights and continuous improvement.

REMS assessment: Demonstrating program effectiveness

The FDA expects sponsors to demonstrate that a REMS is achieving its intended risk mitigation objectives.

Assessment should not be viewed simply as a regulatory reporting requirement. It should provide meaningful evidence that the REMS is achieving its intended risk mitigation objectives and inform decisions about program improvements over time. Meaningful assessment planning begins during REMS design and continues throughout the life of the program. Selecting appropriate measures, ensuring data quality, and evaluating assessment findings over time enable sponsors to determine whether the REMS is effectively supporting safe use and whether opportunities exist to improve program effectiveness while reducing unnecessary burden on patients, health care providers, pharmacies, and the health care system.

An effective REMS is not defined by the number of requirements it contains, but by how effectively those requirements mitigate the product’s identified risks while supporting safe use and appropriate patient access.

Assessment findings should also support continuous improvement. As products mature and additional experience is gained, sponsors should evaluate whether REMS requirements remain appropriate and whether modifications can improve efficiency while continuing to support patient safety.

An evolving safety landscape

Whether sponsors manage a REMS internally or partner with an experienced REMS administrator, planning early remains one of the most important contributors to long-term success.

REMS evolve as products mature, new evidence becomes available and regulatory expectations advance. Ongoing assessment and continuous improvement help ensure the REMS remains aligned with the product’s benefit-risk profile and intended risk mitigation objectives. Sponsors should view REMS as more than a compliance requirement. A well-designed REMS is a dynamic risk management strategy that integrates thoughtful planning, effective governance, adaptable technology, meaningful assessment, and continuous improvement throughout the product life cycle.

Ultimately, choosing the right REMS approach is about more than deciding who will administer the program. It is about selecting a partner with the expertise to design a REMS that reflects the product’s benefit risk profile, generate meaningful evidence that demonstrates program effectiveness, and continually adapt as new information emerges.

Whether managed internally or through an experienced REMS administrator, the goal remains the same: to protect patients, support health care providers, maintain appropriate patient access, and help ensure the benefits of the product continue to outweigh its risks.